On January 25, Project Inform (PI), along with 25 other top HIV advocacy groups, sent a letter to the U.S. Food and Drug Administration (FDA) asking them to give a speedy review to Gilead Science’s application for the anti-HIV medication Truvada (tenofovir and emtricitabine) for pre-exposure…Read More
Category Archives: HIV prevention
The U.S. Centers for Disease Control and Prevention (CDC) in Atlanta has published a new interim guidance for health care professionals on the use of pre-exposure prophylaxis (PrEP) in heterosexual men and women. PrEP involves HIV-negative individuals taking the HIV drug Truvada (tenofovir + emtricitabine) to…Read More
Friday, May 11, 2012 PI Applauds Positive FDA PrEP Decision: Urges Immediate Implementation Steps San Francisco, CA — Project Inform cheered the decision Thursday by an advisory committee to the U.S. Food and Drug Administration (FDA) that the agency should approve tenofovir disoproxil fumarate/emtricitabine (TDF/FTC or…Read More
Aggressive efforts to block new HIV infections are long overdue Noting that the United States has suffered 50,000 new cases of HIV infection a year for well over a decade, Project Inform today said that the time to implement bold new HIV prevention methodologies is long…Read More
On April 24, Project Inform submitted a written testimony to the U.S. Food and Drug Administration’s (FDA) Antiviral Advisory Committee in support of FDA approval of the antiviral drugs TDF/FTC (Truvada) to be offered to prevent HIV transmission among HIV-negative people. Though some groups have tried…Read More
Project Inform strongly applauds the announcement by the California HIV/AIDS Research Program (CHRP) of $11.8 million in funds to study two exceedingly promising new HIV prevention and care strategies: pre-exposure prophylaxis (PrEP) and testing and linkage to care plus treatment (TLC+). CHRP announced April 17 that…Read More
February 6, 2012
Project Inform requests quick FDA review of Truvada for prevention
Thirteen leading AIDS organizations are calling on Gilead Sciences and the U.S. Food and Drug Administration (FDA) to move more quickly on plans to evaluate the use of the HIV drug Truvada (tenofovir and emtricitabine) in HIV-negative men who have sex with men (MSM) and transgender…Read More